Seoul-based bukwang Pharmaceutical is pursuing both growth and defense for its antipsychotic drug, Latuda, as it seeks to expand the medication’s approved uses while simultaneously navigating a patent challenge from Hanwha Pharmaceutical. The moves signal increasing competition within the central nervous system (CNS) pharmaceutical sector, a key area of investment for global drugmakers. Bukwang’s strategy includes clinical trials for new indications and growth of long-acting injectable formulations, reflecting a broader industry trend of maximizing the value of established products.
Bukwang Pharmaceutical Expands Latuda Indication, Faces Patent Challenge
Bukwang Pharmaceutical is moving to broaden the applications of its antipsychotic drug, Latuda, while simultaneously defending the drug’s patent against a challenge from Hanwha Pharmaceutical. The developments signal increased competition within the central nervous system (CNS) pharmaceutical market.
The company recently initiated clinical trials to expand the approved uses of Latuda for the treatment of schizophrenia, according to an announcement. This move aims to solidify Bukwang’s position as a key player in the CNS therapeutics sector.
Simultaneously, Hanwha Pharmaceutical has initiated a patent challenge against Latuda, marking the first such challenge since the drug’s release one year ago. Reports indicate the challenge could intensify competition in the market for treatments targeting schizophrenia and bipolar disorder.
Bukwang Pharmaceutical is also focusing on the development of long-acting injectable formulations, representing a strategic shift towards sustained-release medications. The company views these formulations as a potential “cash cow,” driving future revenue growth.
Kim Ji-heon, head of research and development at Bukwang Pharmaceutical, emphasized the company’s commitment to developing improved new drugs. He stated that the expansion of the company’s pipeline of modified new drugs will be crucial for establishing a stable revenue base.
Bukwang’s efforts to expand Latuda’s indications and defend its patent reflect the broader pharmaceutical industry’s focus on maximizing the lifecycle value of key products. The CNS market, in particular, remains a significant area of investment for pharmaceutical companies globally.
Further details on the adaptive trial are expected to be released in the coming months.
